Dr. Heikki Joensuu from the Helsinki University Central Hospital Discusses Resistance to Imatinib in GIST
Heikki Joensuu, MD, PhD
Advertisement
Articles by Heikki Joensuu, MD, PhD
Dr. Heikki Joensuu from the Helsinki University Central Hospital Discusses the Progress of gastrointestinal stromal tumors (GIST) Treatments
Dr. Heikki Joensuu from the Helsinki University Central Hospital Summarizes the Imatinib for High-Risk high-risk gastrointestinal stromal tumors (GIST) Trial
Advertisement
Latest Updated Articles
Dr. Joensuu Discusses the Progress of GIST TreatmentsPublished: June 8th 2011 | Updated:
Dr. Joensuu Discusses Resistance to Imatinib in GISTPublished: July 5th 2011 | Updated:
Dr. Joensuu on the Imatinib for High-Risk GIST TrialPublished: June 4th 2011 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5